Age-related macular degeneration

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 593-601

  Querques, Giuseppe ^a   Avellis, Fernando Onofrio ^a,b   Querques, Lea ^a,c   Bandello, Francesco ^c   Souied, Eric H ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b UNIVERSITY OF PARMA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Age related macular degeneration; Antivascular endothelial growth factor; Choroidal neovascularization; Drusen; Geographic atrophy

Indexed keywords

ANTIOXIDANT; COMPLEMENT FACTOR H; E 10030; FENRETINIDE; INTEGRIN; OT 551; PAZOPANIB; PEGAPTANIB; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN INHIBITOR; RANIBIZUMAB; TG 100572; TG 100801; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; VERTEPORFIN; VOLOCIXIMAB;

ARTICLE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GEOGRAPHIC ATROPHY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROMOTER REGION; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 79956350091     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S10161     Document Type: Article

References (52)

1. Ehrlich R, Harris A, Kheradiya NS, Winston D, Ciulla TA, Wirostko B. Age-related macular degeneration and the aging eye. Clin Interv Aging. 2008;3:473-482.
2. Nickla DL, Wallman J. The multifunctional choroid. Prog Ret Eye Res. 2010;29:144-168.
3. Chen H, Liu B, Lukas TJ, Neufeld AH. The Aged Retinal Pigment Epithelium/Choroid: A potential substratum for the pathogenesis of age-related macular degeneration. PloS One. 2008;3:e2339.
4. Coleman HR, Chan CC, Ferris FL, Chew EY. Age-related macular degeneration. Lancet. 2008;372:1835-1845.
5. Sun K, Cai H, Tezel TH, Paik D, Gaillard ER, Del Priore LV. Bruch's membrane aging decreases phagocytosis of outer segments by retinal pigment epithelium. Mol Vis. 2007;13:2310-2319.
6. Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology. 2010;117:303-312.
7. Querques G, Querques L, Martinelli D, et al. Pathologic insights from integrated imaging of reticular pseudodrusen in age-related macular degeneration. Retina. 2011;31:518-526.
8. Yehoshua Z, Rosenfeld PJ, Gregori G, et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology. 2011;118:679-686.
9. Klein RJ, Zeiss C, Emily Y, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389.
10. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14:3227-3236.
11. Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet. 2008;40:892-896.
12. Leveziel N, Zerbib J, Richard F, et al. Genotype-phenotype correlations for exudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;14:2263-2271.
13. Scholl HP, Fleckenstein M, Issa PC, Keilhauer C, Holz FG, Weber BHF. An update on the genetics of age-related macular degeneration. Mol Vis. 2007;13:196-205.
14. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age related macular degeneration: A systematic review. Br J Ophthalmol. 2007;91:1177-1182.
15. Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85:486-494.
16. Rosenfeld PJ, David M, Brown DM, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med. 2006;355:1419-1431.
17. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy or neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.
18. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148:409-413.
19. Regillo CD, David M, Brown DM, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145:239-248.
20. Meyer CH, Eter N, Holz FG. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial. Invest Ophthalmol Vis Sci. 2008;49E:Abstr 273.
21. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular agerelated macular degeneration: The EXCITE study. Ophthalmology. December 9, 2010. [Epub ahead of print].
22. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
23. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43-58.
24. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol. 2010;94: 292-296.
25. Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM. A costeffectiveness analysis of three treatments for age-related macular degeneration. Retina. 2010;30:212-221.
26. Bashschur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin B. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: The second year of a prospective study. Am J Ophthalmol. 2009;148:59-65.
27. Patel S. Combination therapy for age-related macular degeneration. Retina. 2009;29(6 Suppl):S45-48.
28. Chen E, Brown DM, Wong TP, et al. Lucentis using Visudyne study: Determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol. 2010;4:1073-1079.
29. Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica. 2009;223:401-410.
30. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116:2141-2148.
31. National Institutes of Health. Safety and efficacy study of small interfering ribonucleic acid (RNA) molecule (C and 5) to treat wet age-related macular degeneration. Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
32. National Institutes of Health. A dose escalation trial of an intravitreal injection of Sirna-027 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD). Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
33. National Institutes of Health. Safety and efficacy of oral PTK787 in patients with subfoveal choroidal neovascularization secondary to agerelated macular degeneration (AMD). Available at: www.clinicaltrials. gov. Accessed April 14, 2011.
34. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multitargeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008;216:29-37.
35. National Institutes of Health. Open-label, pilot study of TG100801 in patients with choroidal neovascularization due to AMD. Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
36. National Institutes of Health. A study to evaluate pazopanib tablets in patients who have neovascular age-related macular degeneration. Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
37. Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration. Nat Rev Drug Discov. 2009;8:922.
38. National Institutes of Health. A study of ARC1905 (anti-C5 aptamer) in subjects with dry age-related macular degeneration. Available at: www. clinicaltrials.gov. Accessed April 14, 2011.
39. National Institutes of Health. A Phase 1, safety, tolerability and pharmacokinetic profile of intravitreous injections of E10030 (anti- PDGF pegylated aptamer) in subjects with neovascular age-related macular degeneration. Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
40. Kuwada SK. Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr Opin Mol Ther. 2007;9: 92-98.
41. Theodossiadis PG, Liarakos VS, Sf ikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol. 2009;147:825-830.
42. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.
43. Huang LL, Coleman HR, Kim J, et al. Oral supplementation of lutein/ zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. Invest Ophthalmol Vis Sci. 2008;49:3864-3869.
44. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: A potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci. 2005;46:4393-4401.
45. National Institutes of Health. Study of fenretinide in the treatment of geographic atrophy associated with dry age-related macular degeneration. 2007, January. http://clinicaltrials.gov/ct2/show/NCT00 429936?term=fenretinide&rank=10. Accessed 19 April 2011.
46. Tanito M, Li F, Anderson RE. Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats. Exp Eye Res. 2010;91:111-114.
47. Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: Results of a Phase II clinical trial. Invest Ophthalmol Vis Sci. 2010;51:6131-6139.
48. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273-1279.
49. Jeganathan VS, Verma S. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol. 2009;20:223-225.
50. ®) for neovascular age-related macular degeneration (AMD): Two-year safety and efficacy results. Invest Ophthalmol Vis Sci. 2009; E-Abstr 3093.
51. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731-1739.
52. ®): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87.